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Abstract
Background
Mycoplasma genitalium is a sexually transmitted infection (STI), and a common cause of
non-gonococcal urethritis (NGU). There is concern regarding the rise in prevalence of M.
genitalium and rates of resistance to macrolide antibiotics. International backpackers repre-
sent a unique population that may be at an increased risk of STIs. The purpose of this study
was to determine the prevalence of M. genitalium and antibiotic resistance in international
backpackers.
Methods
First void urine samples were obtained utilising opportunistic sampling from 294 non-treat-
ment-seeking international backpackers at a variety of hostels in Cairns, Queensland Aus-
tralia. Participants also answered a fixed-answer survey regarding sociodemographic
characteristics and sexual risk behaviours. Samples were tested for M. genitalium, Chla-
mydia trachomatis and Neisseria gonorrhoeae using polymerase chain reaction (PCR).
Samples positive for M. genitalium were investigated for macrolide resistance-associated
mutations in the 23S rRNA genome at positions A2058G, A2058C, A2058T, A2059G and
A2059C (Escherichia coli numbering).
Results
Of the 294 samples, 23 failed the internal control. The prevalence of M. genitalium was
1.8% (5/271, 95% confidence interval [CI] ± 1.58), C. trachomatis was 4.1% (11/271, 95%
CI ± 2.36) and N. gonorrhoeae was not detected. Macrolide resistance-associated muta-
tions were identified in 40% (2/5) of M. genitalium-positive samples. M. genitalium infection
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was associated with reporting symptoms (odds ratio [OR] 14.36, 95% CI 2.17–94.94, p <
0.05).
Conclusions
M. genitalium and C. trachomatis are relatively common amongst non-treatment seeking
international backpackers, but may not differ from Australian population prevalence. This
article provides evidence to further support the increased utilisation of M. genitalium PCR in
the diagnosis of NGU, and for macrolide resistance testing for all identified M. genitalium
infections.
Introduction
Mycoplasma genitalium is a sexually transmitted infection (STI) and an established cause of
non-gonococcal urethritis (NGU), being isolated as the most common pathogen in 6–50% of
people presenting with NGU [1]. Population prevalence of M. genitalium is estimated in a
national Danish study, in a range of 1.1–3.3%; with this same study also suggesting that the
prevalence of M. genitalium may be increasing [2]. In Australia, the prevalence of M. genita-
lium rages from 2.1–13% depending on the population tested [3–6]. The majority of people
infected with M. genitalium are likely to be asymptomatic, with 52% asymptomatic in one
cohort study [7,8].
Clinical symptoms
Up to 6% of male urogenital complaints may be caused by M. genitalium, which may include:
balanoposthitis, urethral discharge and/or dysuria [9–15]. M. genitalium may also be associ-
ated with chronic prostatitis and epididymitis [11–16]. In females, M. genitalium is associated
with cervicitis, pelvic inflammatory disease, urethritis and infertility [17–19]. M. genitalium
has also been associated with preterm birth and spontaneous abortion [19].
Treatment of M. genitalium
In Australia, the mainstay treatment of NGU is single dose 1 gram azithromycin or a 7-day
course of doxycycline 100 mg twice daily [20]. One review of recent literature concluded that
single-dose azithromycin can induce macrolide resistance and is ineffective if macrolide resis-
tance is present [7]. Although more efficacious than doxycycline (failure rates of up to 83%),
azithromycin therapy only resulted in cure of M. genitalium in 40–88% of cases; however, this
depended on population resistance levels [7]. Prolonged courses of azithromycin, although
slightly more efficacious and less likely to induce macrolide resistance, also remained ineffec-
tive if macrolide resistance is already present [7]. In cases of resistance, moxifloxacin 400 mg
once daily for 10–14 days remained effective in> 88% of cases, however concerns exist regard-
ing emerging fluoroquinolone resistance in M. genitalium [7].
Macrolide resistance
Resistance to macrolide class antibiotics has become an increasing concern both within recent
literature and in clinical practice, with resistance in M. genitalium reported as high as 58.0% in
one study investigating attendees at a Canadian sexual health clinic [8]. The first study demon-
strating resistance of M. genitalium to macrolide antibiotics, namely azithromycin, was
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published in 2006 [21]. In 2008, three mutations at the 2058 and 2059 (A2058G, A2059G and
A2058C, Escherichia coli numbering) positions in the region V of the 23S rRNA gene were
identified to confer clinical macrolide resistance; findings that were consistent with similar
research in other Mollicutes [22,23]. Two additional mutations (A2059C and A2058T) were
identified using high resolution melt analysis in 2012 [24]. Macrolide resistance-associated
mutations have been shown to correlate with microbiological and clinical treatment failure
(p = 0.013 and p = 0.024, respectively) [25].
In Australian studies, treatment failure with azithromycin has increased from 16% in a
2005–2007 cohort, to 31% in a 2007–2009 cohort of the same patient population [24,26]. In a
recent prospective cohort study, also conducted in Australia, treatment failure with single-
dose azithromycin was seen in 39% of participants [27]. Macrolide resistance-associated muta-
tions were detected in 36% of patients, of which 87% failed single-dose azithromycin treatment
[27]. These studies suggest that in Australia, resistance-associated mutations in M. genitalium
are becoming increasingly prevalent. Alarmingly, a recent study in Greenland detected macro-
lide resistance-associated mutations in 100% of M. genitalium positive samples [28].
M. genitalium and international travellers
M. genitalium prevalence and antibiotic resistance has not been described in any travelling
population. International backpackers are defined as any international traveller staying at least
one night in a hostel-style accommodation, and represents an under-studied population in
Australia [29]. The prevalence of STI amongst international travellers ranges between 1.6–
27.1% for C. trachomatis, 0–36.7% for N. gonorrhoeae, 1.3–24.5% for Treponema pallidum
(syphilis), 0.07–1.3% for Trichomonas vaginalis, 1.3–24.5% for herpes simplex virus (HSV),
6.4–9.6% for human papillomavirus (HPV) and 0–4.1% for HIV depending on the study
design and specific population sampled [30–39].
Sexually transmissible infections and high-risk sexual behaviour, such as inconsistent con-
dom use and casual sex, alcohol use and engaging in illicit drug use, are reasonably common
amongst international travellers in Australia[30–35,40]. During travel, 48–94% of backpackers
reported engaging in new sexual partnerships and 41–80% reported inconsistent condom use
with new sexual partnerships whilst in Australia [30–34,40]. For this reason, is it believed that
backpackers may represent a group at high risk of being infected with M. genitalium.
The aims of this study are to describe the point prevalence of M. genitalium and rates of
macrolide resistance-associated mutations within the Far North Queensland backpacker pop-
ulation. Additional primary aims include establishing correlations between M. genitalium pos-
itivity and sexual risk behaviour, such as frequency of sexual partners, condom use and travel
history.
Methods
Participants
This cross-sectional population-based study was undertaken in Cairns, Queensland Australia
between the months of May and June of 2016. During this period, first void urine (FVU) sam-
ples and survey data were collected from international backpackers staying in hostel-style
accommodation using opportunistic sampling. Permission was sought from the management
of these hostels to recruit participants on their premises, provide sexual health information
and distribute condoms and water-based lubricants. Hostels in three suburbs of Cairns were
contacted, including: sixteen hostels in Cairns City (six agreed to participate) three hostels in
Cairns North (all agreed) and one hostel in Parramatta Park (agreed). These hostels were vis-
ited in the afternoons and evenings in an attempt to maximise the number of people engaged,
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as travellers tended to return to hostels from tourist activities in the late afternoon. The
research team returned to locations repeatedly, often leaving one or two weeks between visits,
until the target sample size was reached. Subjects were only allowed to participate once, how-
ever those who requested an additional STI screen were welcome to have one; these additional
results did not form part of our dataset. We anticipated a conservative prevalence of 3% in this
population, therefore 279 participants would be required to obtain a 95% CI of ± 2%; this fig-
ure represents our minimum sample size.
International backpackers aged 18 years or older who have stayed, or are planning to stay,
at least 1 night in a backpacker hostel were included in this study. Participants were required
to have the capacity to provide informed consent, including sufficient English proficiency to
fully understand the consent form. Exclusion criteria prevented the enrolment of those under
the age of 18 years and Australian citizens. Participants were approached at random and were
provided both written and verbal information about the project. Confectionaries were offered
to those who participated, with condoms, personal lubricant, and information about STIs and
accessing healthcare in Cairns were freely distributed.
Questionnaire
Written informed consent was obtained from all participants prior to commencing the online
survey using the program Google Forms™ (Google Incorporated). Participant provided infor-
mation included: sociodemographic characteristics, arrival with or without a partner, whether
they had stayed at least one night in a backpacker hostel, and their total time thus far in, and
total expected stay in, both Australia and Cairns. Included in this survey were a range of ques-
tions regarding sexual behaviour, including: the number of sexual partners in the 12 months
prior to leaving their country of origin, the number of sexual partners and condom use with
these partners whilst in Australia and in Cairns specifically. Travel to a country prior to visiting
Australia, the number of sexual partners and condom use in this country were also recorded.
Finally, participants provided responses for whether they currently experienced symptoms
typical of an STI, whether they had been diagnosed with an STI in the past and whether they
had received antibiotic therapy in the last three months S1 File. Participant’s responses were
de-identified prior to statistical analysis and re-identified in the event of a positive result. Data
were stored in Google Drive™ (Google Incorporated) which requires 2-factor authentication to
retrieve.
Specimen collection and analysis
Participants were provided with verbal instruction and asked to supply a FVU sample, all of
which were self-collected by participants. Urine specimens were transferred to 1.5 mL micro
centrifuge tubes within 3 hours of collection and immediately frozen at –20 degrees Celsius in
a freezer with 24-hour temperature monitoring. Following each 4-week period of data collec-
tion, samples were sent in a thermal box with a frozen gel pack via overnight courier to The
Women’s Hospital in Melbourne, Victoria to undergo molecular testing in two batches. Detec-
tion of M. genitalium and macrolide resistance was undertaken simultaneously, utilising the
SpeeDx PlexPCR™M. genitalium ResistancePlus™ assay (SpeeDx Pty. Ltd., Australia) and Roche
LightCycler1 480 instruments (Roche Products Pty. Ltd., Australia), following the manufac-
turer’s instructions for both. This assay determines the presence of M. genitalium by detection
of the MgPa gene. This assay simultaneously identifies the presence of 5 mutations at positions
A2058G, A2059G, A2058C, A2059C and A2058T (E. coli numbering) in the 23S rRNA genome
of M. genitalium associated with resistance to macrolide-based antibiotics. Sensitivity for the
detection of M. genitalium using this assay is 99.1% and specificity is 98.5% when compared to
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reference methods (qPCR targeting the 16S rRNA gene). Sensitivity for detection of macrolide
resistance associated mutations is 97.4% and specificity is 100% when compared to reference
methods (high resolution melt analysis) [41].
Efficacy of the DNA extraction was assessed and the presence of PCR inhibitors was identi-
fied by amplifying a 260bp region of the human beta-globin gene, using methods described in
prior literature [42,43]. Detection of C. trachomatis targeting the ompA gene and N. gonor-
rhoeae targeting the OPA gene was conducted using published in house-assays [44,45]. Sam-
ples testing low-positive for the presence of N. gonorrhoeae were confirmed by the detection of
the PorA pseudogene using methods previously described [46].
Follow up
Participants with positive test results were contacted with their result and resistance status to
best facilitate appropriate care. This was completed by following a semi-scripted ethics-
approved re-contact protocol, first by phone (if provided) and then by email.
Data analysis
Specimen data were also entered into Microsoft Excel™ (Microsoft Corporation) and were
linked to matched survey data. Data were coded within Excel and analysed by IBM Statistical
Package for the Social Sciences version 23™ (International Business Machines Corporation).
Proportions with 95% CI were calculated for M. genitalium and C. trachomatis prevalence.
Pearson’s chi-squared test for independence (plus Yates’ correction for continuity) and Fish-
er’s exact test were used to compare categorical variables. Spearman’s ρ correlation coefficient
(r) was used to compare continuous variables to dichotomous variables (sex, STI positivity,
arrival with sexual partner etc.). Differences between male and female correlation coefficients
were performed on all statistically significant correlations, where the critical value of z at
p = 0.05 level was -1.96 or 1.96, with observed z values (zobs) outside the critical value of z
considered significant.
Ethics
Ethics approval was granted by the James Cook University Human Research Ethics Committee
April 26th 2016. Ethics approval number H6483.
Results
Data were collected from ten locations over twenty-nine separate occasions during the two-
month data collection period. Six participants were removed from the dataset due to selecting
Australia as their country of origin on the survey. In total, we recruited 157 males (53.0%) and
139 females (47.0%), resulting in a total of 296 completed surveys and 294 FVU samples (two
participants were unable to produce urine samples). Of the 294 FVU samples, 23 failed the
internal control due to inhibitors in the urine, resulting in 271 valid urine sample results, all
with paired survey data.
Participant demographics
The median age of all participants was 23.4 years (interquartile range [IQR] 21.4–26.0). For
males, the median age was 23.4 (IQR 21.6–26.2) and for females the median age was 23.1 (IQR
20.9–26.0). Twenty-two-point six percent of all participants were aged 18–20 years, 45.3% were
aged 21–24 years and 32.1% were aged 25 years. The majority of participants originated from
European countries (85.5%), with the remainder originating from North America (10.5%),
M. genitalium in the Far North Queensland backpacker population: Prevalence and azithromycin resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0202428 August 28, 2018 5 / 14
South America (1.4%), Asia (1.4%) and Oceania (0.7%); no participants originated from conti-
nental Africa. Of the European counties, 37.8% were from the United Kingdom of Great Britain
and Northern Ireland, 18.5% were from Germany, 6.4% were from the Netherlands, 5.7% were
from France and 4.4% were from Sweden; 12.9% were from other European countries.
Prevalence of M. genitalium and macrolide resistance
Five samples tested positive for M. genitalium out of the 271 valid urine tests, resulting in a prev-
alence of 1.8% (5/271, 95% CI ± 1.58). None of these five sample were also positive for C. tracho-
matis or N. gonorrhoeae. Two people testing positive for M. genitalium reported experiencing
symptoms, therefore the asymptomatic prevalence of M. genitalium in this sample was 1.3% (3/
240, 95% CI ± 1.43). Independent variables obtained from the survey were explored for associa-
tions with M. genitalium positivity, the only statistically significant association identified was
reporting symptoms (odds ratio [OR] 14.36, 95% CI 2.17–94.94, relative risk [RR] 12.31, 95%
CI 2.25–67.37, p< 0.05). In males, three samples were positive, resulting in a prevalence of
2.2% (3/135, 95% CI ± 2.47). In females, two samples were positive, giving a prevalence of 1.5%
(2/136, 95% CI ± 2.04). Of the five positive samples, macrolide resistance-associated mutations
were identified in two, demonstrating a 40% rate of resistance in our sample population. The
sociodemographic and sexual risk behaviours exhibited by those subjects positive for M. genita-
lium are outlined in Table 1. Antibiotic use in the past 3 months was reported by 18.9% of par-
ticipants, with the majority (71.4%) unable to recall what was prescribed.
Prevalence of C. trachomatis and N. gonorrhoeae
Eleven samples tested positive for C. trachomatis, resulting in a prevalence of 4.1% (11/271,
95% CI ± 2.36) in our sample population. The number of evaluable asymptomatic subjects was
Table 1. Sociodemographic and sexual risk behaviour of participants positive for M. genitalium.
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5
Resistance mutation Present Absent Absent Present Absent
Age (years) 23 18 25 28 25
Gender Male Female Male Female Male
Country of origin Italy United Kingdom Canada Belgium United States of America
Arrival with partner No No No No No
Time spent in Australia > 12 weeks > 12 weeks 4–12 weeks 2–4 weeks > 12 weeks
Time spent in Cairns > 12 weeks 4–12 weeks < 2 weeks < 2 weeks 4–12 weeks
Number of sexual partners prior to travel^ > 10 2 1 2 4
Number of new sexual partners in Australia > 10 3 2 0 5
Number of new sexual partners in Cairns > 10 1 0 0 3
Frequency of condom use with new partners in Australia Sometimes Never Never - Sometimes
Country visited prior to Australia Spain - New Zealand - Indonesia
Number of new partners in country prior to Australia1 > 10 - 2 - 3
Frequency of condom use with new partners prior to Australia Sometimes - Never - Always
Past diagnosis of an STI No No No Yes Yes
Symptomatic§ No Yes Yes No No
Antibiotics in the preceding 3 months No No No Uncertain No
^. Approximate number of sexual partners in the 12 months prior to leaving the country of origin.
1. Approximate number of sexual partners in the country visited immediately prior to entering Australia, not including stopovers 24 hours in length.
§. Symptoms including: pain when urinating, pain with sexual intercourse, discharge or other symptoms that would suggest to participants that they may have an STI
https://doi.org/10.1371/journal.pone.0202428.t001
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240, adjusted from 263 for the 23 samples from asymptomatic individuals whose samples
exhibited PCR inhibition. Ten participants who tested positive for C. trachomatis denied
symptoms and one was uncertain, resulting in an asymptomatic prevalence of 4.2% (10/240,
95% CI ± 2.54). In males, six samples were positive, resulting in a prevalence of 4.4% (6/135,
95% CI ± 3.46). In females, five samples were positive, resulting in a prevalence of 3.7% (5/136,
95% CI ± 3.17). Independent variables obtained from the survey were explored for associations
with C. trachomatis positive. Those participants arriving in Australia with a sexual partner
were more likely to test positive for C. trachomatis (OR 5.21, 95% CI 1.27–20.34, p< 0.05),
however the effect size was small (Crame´r’s V [V] = 0.15). There was small but significant cor-
relation between the number of sexual partners engaged with in Cairns and positivity for C.
trachomatis (r = .131, p< 0.05), this correlation appeared to be stronger and significant in
females (r = .208, p< 0.05 vs r = .038, not significant); however, the correlation coefficient did
not differ significantly between groups (zobs = -1.39). No other statistically significant associa-
tions were found between C. trachomatis positivity and surveyed variables, including symp-
toms. Nine samples were low-positive for N. gonorrhoeae on initial testing, these were shown
to be equivocal on confirmation testing of the PorA pseudogene sequence, and therefore con-
sidered negative.
Sexual risk behaviour
Table 2 summarises the sexual behaviour of participants, categorised by gender. Twenty-one
percent of participants arriving in Australia without a sexual partner engaged in sex with one
partner, and 61.0% engaged in sex with 2 or more partners, whilst in Australia. Twenty-point
six percent engaged in sex with one sexual partner whilst in Cairns and 24.6% engaged with 2
or more partners in Cairns. Of those engaging in sex with new partners whilst in Australia,
24.5% always used condoms, 38.6% sometimes used condoms, 10.5% used condoms infre-
quently, and 26.4% never used condoms.
Discussion
In this cross-sectional population study of 294 non-treatment-seeking international backpack-
ers in Cairns, Queensland Australia, the prevalence of M. genitalium infection was 1.8%, the
prevalence of C. trachomatis was 4.1% and the prevalence of N. gonorrhoeae was 0%. Macrolide
resistance-associated mutations were identified in 40% of M. genitalium-positive samples.
Despite evidence of high risk sexual behaviour, with 61.0% engaging in sexual activity with
multiple partners and 75.5% reporting inconsistent or absent condom use, prevalence of M.
genitalium was less than that of other Australian population groups, such as 13% in at-risk
youth accessing health services, 2.1% in men who have sex with men in men-only saunas and
2.4% in females attending primary healthcare services [6,47,48]. Only one other study has
investigated the prevalence of M. genitalium and macrolide resistance in the same geographical
area, in a cohort of incarcerated men, where the prevalence was 5.71% and macrolide resis-
tance was 25% [3]. High rates of macrolide resistance have also been reported in other centres
within the state of Queensland, with one study reporting macrolide-associated resistance
mutations in 63.6% of samples collected from 2011–2017 [49]. The rates of macrolide resis-
tance-associated mutations identified in this study are consistent with that of prior Australian
research, and support the notion that resistance is increasing in Australian samples, with 16%
identified in a 2005–2007 cohort, 19.5% in a 2007–2008 cohort, 43% in a 2008–2011 cohort,
25% in a 2012–2013 cohort to 40% in our 2016 cohort [3,24,26,50].
Our research supports statements in recent literature calling for increased molecular testing
for M. genitalium in primary healthcare environments and recall for test of cure in all patients
M. genitalium in the Far North Queensland backpacker population: Prevalence and azithromycin resistance
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Table 2. Reported sexual behaviour by gender.
Sexual Behaviour Males Females Total
n/total % n/total % n/total %
Arrival with partner
Yes 13/157 8.3 11/139 7.9 24/296 8.1
No 144/157 91.7 128/139 92.1 272/296 91.9
Number of sexual partners prior to travel^
0 5/157 3.2 6/139 4.3 11/296 3.7
1 33/157 21.0 40/139 28.8 73/296 24.7
2–5 67/157 42.7 69/139 49.6 136/296 45.9
 6 52/157 33.1 24/139 17.3 76/296 25.7
Number of new sexual partners in AustraliaΔ
0 31/144 21.5 18/128 14.1 49/272 18.0
1 28/144 19.4 29/128 22.7 57/272 21.0
2–5 47/144 32.6 52/128 40.6 99/272 36.4
 6 38/144 26.4 29/128 22.7 67/272 24.6
Number of new sexual partners in CairnsΔ
0 81/144 56.3 68/128 53.1 149/272 54.8
1 30/144 20.8 26/128 20.3 56/272 20.6
2–5 22/144 15.3 28/128 21.9 50/272 18.4
 6 11/157 7.6 6/128 4.7 17/272 6.3
Condom use with new partners in Australia‡
Always 32/111 28.8 22/109 20.2 54/220 24.5
Sometimes 40/111 36.0 45/109 41.3 85/220 38.6
Infrequently 11/111 9.9 12/109 11.0 23/220 10.5
Never 28/111 25.2 30/109 27.5 58/220 26.4
Number of sexual partners en route to Australia1†
0 30/77 39.0 33/58 56.9 63/135 46.7
1 19/77 24.7 10/58 17.2 29/135 21.5
2–5 20/77 26.0 10/58 17.2 30/135 22.2
 6 8/77 10.4 5/58 8.6 13/135 9.6
Condom use with partners en route to Australia^
Always 16/46 34.6 8/25 32.0 24/71 33.8
Sometimes 21/46 45.7 12/25 48.0 33/71 46.5
Infrequently 2/46 4.3 - - 2/71 2.8
Never 7/46 15.2 5/25 20.0 12/71 16.9
Past diagnosis of an STI
Yes 29/157 18.5 35/139 25.2 64/296 21.6
No 126/157 80.3 102/139 73.4 228/296 77.0
Unsure 2/157 1.3 2/139 1.4 4/296 1.4
Symptomatic§
Yes 3/157 1.9 10/139 7.2 13/296 4.4
No 143/157 91.1 120/139 86.3 263/296 88.9
Unsure 11/157 7.0 9/139 6.5 20/296 6.8
^. Approximate number of sexual partners in the 12 months prior to leaving the country of origin.
1. Approximate number of sexual partners in the country visited immediately prior to entering Australia, not including stopovers 24 hours in length.
†. Data expressed as the proportion of participants who visited another country en route to Australia.
Δ. New sexual partners are defined as those participants who reported arriving in Australia without a partner who engaged in sexual intercourse whilst in Australia or
Cairns.
‡. Condom use in those who arrived in Australia without a partner and engaged in sexual intercourse, note that 2 male participants and 1 female participant provided
invalid responses.
^. Condom use in those reporting engaging in sexual intercourse in the country visited en route to Australia, note that 1 male participant provided an invalid response.
§. Symptoms including: pain when urinating, pain with sexual intercourse, discharge or other symptoms that would suggest to participants that they may have an STI
https://doi.org/10.1371/journal.pone.0202428.t002
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presenting with M. genitalium-positive NGU [7]. This is becoming increasingly pertinent
given the growing body of evidence supporting the long-term and irreversible negative conse-
quences of M. genitalium infection in women. Given the accumulative evidence for the role of
M. genitalium in NGU and increasing prevalence of macrolide resistance, our study supports
the call to update empirical treatment guidelines for NGU. This is relevant given the overall
lack of access to, and utilisation of, M. genitalium PCR testing resulting in a considerable reli-
ance on empirical guidelines in the treatment of NGU. Following the advent of commercially
available assays that simultaneously detect M. genitalium and macrolide resistance-associated
mutations, increased application of molecular techniques in the diagnosis of NGU and in
asymptomatic screening programs have the potential to accurately guide appropriate antibiotic
therapy, reduce transmission of resistant strains and prevent long-term consequences of
asymptomatic infection [24,41]. In line with recent research, the guidelines for management of
PCR-proven M. genitalium infection recommenced by the Australian STI Management
Guidelines have changed. Antimicrobial recommendations for M. genitalium infection known
or suspected to be susceptible to macrolides includes doxycycline 100 mg twice daily for seven
days followed by either azithromycin 1 gram as a single dose or azithromycin 1 gram followed
by 500 mg for three days. M. genitalium infection known or suspected to be resistant to macro-
lides is recommended to be managed with doxycycline 100 mg for seven days followed by
moxifloxacin 400 mg for seven days [51]. Despite this further clarity regarding antimicrobial
selection for the management of M. genitalium, its routine screening in international back-
packers is difficult to support given the low prevalence, uncertainties regarding contact tracing
and difficulty with adequate follow up.
The prevalence of C. trachomatis in our study was comparable to a number of other studies
in Australia, with one Australian review reporting a mean C. trachomatis prevalence of 4.6%
[52]. This was consistent with previous population-level studies of international backpackers
in Australia, with 4.3% reported in one recent study and 3.5% in another [30,32]. In two other
Australian studies utilising population-level sampling of international backpackers, C. tracho-
matis rates were higher than reported in this study, at 11.9% in unsupervised screening and
7.7% in sexually active backpackers, both at hostels [31,35]. Higher rates of C. trachomatis
infection in international backpackers have been reported, but these studies represented treat-
ment-seeking groups attending sexual health clinics. Our study has been unable to replicate
previously-reported associations between age, rates of partner change and inconsistent con-
dom use to C. trachomatis positivity amongst backpackers. This may be a reflection on the
small sample size and relatively few positive samples obtained, although our study is not the
first to be unable to make any significant association between a variety of sociodemographic
factors and sexual behaviours with C. trachomatis positivity in backpackers [32,34]. Inconsis-
tent condom use, reporting 2 or3 sexual partners during travel and reporting a known STI
contact were risk factors for C. trachomatis infection in male backpackers in one study, how-
ever these may not differ from non-backpacker groups [33].
Prevalence of N. gonorrhoeae in our study was also equivalent to prevalence seen in other
population-level studies screening international backpackers, with 0% reported in two studies,
and 0.72% in another study of health-seeking backpackers accessing sexual health services; this
is likely due to the fact that N. gonorrhoeae is predominately symptomatic and the sample
group was mostly asymptomatic [30,31,34].
M. genitalium was associated with reporting STI symptoms, but not in C. trachomatis infec-
tion, in our sample. Infection with C. trachomatis was weakly associated with arriving in Aus-
tralia with a sexual partner. This outcome is likely due to skewed data, as two of the
participants testing positive for C. trachomatis were in a long-term monogamous relationship
with each other. The number of sexual partners engaged with in Cairns was also associated
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with C. trachomatis infection, but not the number of sexual partners engaged with in any other
location. Engaging in sex with multiple partners whilst in Cairns was reported by 54.5% of
those testing positive for C. trachomatis. This may suggest that backpackers actively engage in
regular sexual health checks, as rates of partner change are only significantly correlated with C.
trachomatis positivity at the most recent travel destination, suggestive of recently obtained
infection as opposed to asymptomatic carriage. However regular sexual health seeking behav-
iour has not been the case in previous reports [30].
Owing to the high frequency of recent antibiotic use, there exists the potential that the prev-
alence of STIs in this population may be greater than reported. This is especially relevant when
considering multiple serovars of C. trachomatis remained susceptible (in varying degrees) to
macrolides, tetracyclines, fluoroquinolones and β-lactam antibiotics in a recent in vitro study
[53]. Having a past STI diagnosis was reported by 21.6% of participants, consistent with the
notion that international travellers report a past diagnosis of STI more often than non-travel-
ling population (15% vs 10%, respectively, p< 0.001), in one Australian study [34].
This study is limited in that the only specimens collected were FVU samples. Evidence sug-
gests that for females, vaginal swab specimens are the most sensitive specimen for the detection
of M. genitalium (despite the absence of an established gold standard method for detection of
M. genitalium), followed by cervical swabs and then urine samples (κ = .923, κ = .843 and κ =
.687 respectively), with another study reporting the sensitivity of 85.7% for vaginal swab sam-
ples, 74.3% for endocervical swabs, 61.4% for urine and 24.3% for rectal swabs [54,55]. This
may have resulted in an under-representation of M. genitalium-positive females in our study.
The overall prevalence of M. genitalium in this population may be higher if other anatomical
sites were included. This study is also limited in that a number of other known STIs were not
investigated. This was due in part to the financial and logistical constraints of collecting blood
samples in a hostel environment and due to a number of other STIs existing beyond the scope
of this project. An additional limitation of this study was the number of samples that were
unable to be assessed owing to the presence of inhibitors of PCR in the urine. There exists the
possibility that subjecting specimens to freeze-thaw cycles may alter the sensitivity of PCR test-
ing. The impact of this limitation could have been decreased with the utilisation of DNA/RNA
stabilising agents, allowing samples to be stored at ambient temperature [54]. The sensitivity of
the detection of STIs is influenced by the time since last micturition and the participant’s abil-
ity to correctly collect a FVU sample, and in females factors such as degree of contamination
of urine samples with cervical or vaginal secretions may increase the sensitivity of M. genita-
lium testing [54]. Further limitations include not assessing additional sexual risk behaviours,
such as: alcohol or drug use, time since last STI check, types of sexual activity, or whether par-
ticipants were utilising the services of sex workers. Participants were also not asked if they
were engaging in sex with Australian citizens or other backpackers, which limits this study’s
capacity to assess the risk of transmission of STIs and antibiotic resistance from international
sources to Australians or vice versa. Another limitation of this study is that there was no formal
follow up of STI-positive participants, and therefore we are unable to comment on the rela-
tionship between microbiological and clinical macrolide resistance. This study was also limited
by the small sample size, and unexpectedly low number of participants testing positive for
STIs.
M. genitalium and C. trachomatis were relatively common STIs in our cohort of non-treat-
ment-seeking international backpackers in Cairns, Queensland Australia. International back-
packers appear to be a relatively heterogeneous group, and research into this collective may
not describe backpackers as a whole. The overall paucity of evidence supporting the categorisa-
tion of international backpackers as a high-risk group for STIs and the small volume of evi-
dence suggesting no difference in (and in the case of M. genitalium, reduced) prevalence of
M. genitalium in the Far North Queensland backpacker population: Prevalence and azithromycin resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0202428 August 28, 2018 10 / 14
STIs when compared to non-travelling groups, makes the justification for outreach sexual
health clinics in hostels unfavourable. Concerns regarding the transmission of antibiotic-resis-
tant strains of STIs are supported by a cumulative body of evidence that proposes macrolide
resistance-associated mutations are becoming increasingly prevalent in M. genitalium
[3,24,26,50]. The unease regarding the spread of antibiotic resistance is heightened when con-
sidering the behaviours of sexually active itinerant groups with local populations, and even
more so when considering the potential for empirical therapies to induce macrolide resistance
in otherwise sensitive M. genitalium strains [7,32,56–58]. Current guidelines regarding the
treatment of NGU may be outdated regarding antibiotic resistance patterns, resulting in an
environment where selection pressure for the development of resistance is intensified. Despite
this evidence, the empirical management of NGU in Australia continues to utilise a 1 gram
stat dose of azithromycin, with the intent being to treat chlamydial NGU, which is thought to
cause more serious long-term sequelae [59]. However, evidence suggests the potential for sig-
nificant morbidity associated with M. genitalium, especially in females, and has resulted in
appeals within the literature for M. genitalium to be regarded with more significance [7,59,60].
Our research provides continued support for the implementation of now commercially avail-
able assays which simultaneously detect M. genitalium and macrolide resistance and regular
screening of high risk groups, a risk category international backpackers may inhabit [59].
However, the data does not support a clear public health benefit from hostel-based sexual
health outreach services or the regular screening of low to medium risk asymptomatic individ-
uals for M. genitalium.
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